Targeting a Natural Repair System to Restore Brain Health

Episode Summary

Executive Summary: The episode examines Athera Pharma’s rationale for targeting the HGF/MET neurotrophic pathway in neurodegenerative disease, especially Alzheimer’s. COO Rachel Lennington argues that amyloid-focused therapies address only part of the disease biology and that Athera’s small-molecule modulator, Fosgonometin, may offer neuroprotective and anti-inflammatory benefits. The discussion also covers trial design, prior setbacks, Parkinson’s data, an ALS program, and investor expectations.

Main Topics: Alzheimer’s unmet need and therapeutic gaps (Priority: 5/5): Lennington says Alzheimer’s still has major unmet need, with only a few drug classes available and many patients lacking effective options. Why amyloid/tau-focused approaches are not enough (Priority: 5/5): The conversation argues that amyloid clearance has not stopped clinical decline, suggesting broader disease mechanisms like inflammation and excitotoxicity must be targeted. HGF/MET pathway as a neurotrophic strategy (Priority: 5/5): Athera is pursuing positive modulation of the HGF/MET pathway to reduce inflammation, promote neuroprotection, and potentially reduce protein pathology. Fosgonometin mechanism and clinical program (Priority: 5/5): Fosgonometin is described as an oral HGF positive modulator currently being tested in a phase 2/3 Alzheimer’s study designed around cognition and function in mild to moderate disease. Interpreting prior trial failures (Priority: 4/5): Earlier phase 2 studies in Alzheimer’s and Parkinson’s disease dementia/DLB missed primary endpoints, but Athera cites small sample size, endpoint selection, and subgroup signals as reasons to continue. Pipeline expansion into Parkinson’s and ALS (Priority: 4/5): Beyond Alzheimer’s, Athera is exploring HGF/MET modulation in Parkinson’s and advancing ATH-1105 for ALS, supported by encouraging preclinical results. Financing and investor messaging (Priority: 3/5): Lennington addresses Athera’s public-market volatility, current cash position, and the need to educate investors about a novel mechanism outside the amyloid/tau paradigm.

Key Arguments: Alzheimer’s remains severely underserved, with limited approved therapies and 6.7 million Americans affected. Disease-modifying success in Alzheimer’s has been difficult because cognition and daily-function measures are subjective, variable, and require long studies. Advances in biomarkers are making neurodegeneration trials easier and helped enable recent amyloid antibody approvals. Amyloid clearance alone does not stop decline, implying additional mechanisms such as inflammation and excitotoxicity are important. The HGF/MET pathway is a natural repair and signaling system that can reduce inflammation, support neuroprotection, and possibly lower protein pathology. Athera intentionally chose a more advanced mild-to-moderate Alzheimer’s population for shorter, more practical studies where most patients are diagnosed today. The prior phase 2 endpoint was electrophysiologic (ERP P300 latency), chosen for translational reasons, but it may have worked better in single-site settings than in multicenter trials. An interim analysis by an independent committee supported continuing the phase 2/3 study, suggesting the full dataset could still be statistically successful. Parkinson’s data were exploratory and underpowered, but signals in cognition and preclinical motor/alpha-synuclein models encouraged further work. The ALS candidate ATH-1105 shows promising preclinical survival and motor benefits, and the company expects to enter the clinic soon.

Data Points: Americans living with Alzheimer’s: 6.7 million - Lennington cites the current U.S. Alzheimer’s burden as evidence of unmet need. Alzheimer’s drug classes: 3 classes - She says there are only about three classes of drugs to treat Alzheimer’s disease. Phase 2/3 Alzheimer’s study duration: 6 months - Athera designed Lift AD for a shorter treatment window in mild-to-moderate Alzheimer’s. Recent anti-amyloid trial duration: 18 months - Lennington contrasts Athera’s design with earlier-stage amyloid studies that ran much longer. Recent anti-amyloid trial size: 1,800 patients - She references large amyloid studies as an example of lengthy, resource-intensive trials. Patients diagnosed in mild to moderate Alzheimer’s: 85% - Athera says most diagnosed patients are in this more advanced population. Phase 2 study size: small 77 percent study - The transcript describes an early Fosgonometin Alzheimer’s study as small and not statistically significant; the wording appears to reflect the source transcript. Interim analysis sample: first 100 patients - An independent committee reviewed the first 100 completers and advised continuing. Projected total patients for continuation: next 200 or so patients - The committee said the full study could become statistically significant if later patients performed similarly. Parkinson’s study enrollment: around 28 patients - Enrollment was stopped early to reallocate resources to Alzheimer’s. Parkinson’s planned enrollment: about 75 patients - The Parkinson’s study was intended to enroll roughly 75 patients. Fosgonometin dose signal in Parkinson’s: 40 mg - Lennington says all patients in the 40 mg group improved on cognitive measures. Athera IPO year: 2020 - The company went public in 2020. IPO price: $17/share - The host notes the initial public offering price. All-time stock high: $34/share - The company stock reportedly traded as high as this level. Current stock price: around $3/share - The host describes the share price at the time of recording. Market capitalization: a little over $100 million - The host characterizes the company’s then-current valuation. Cash on hand: approximately $150 million - Lennington says the company ended the prior year with this amount of cash.

Pivotal Quotes: "There is definitely a need for new therapies. There's not been a lot of progress in this space." — Rachel Lennington: On the unmet need in Alzheimer’s disease and why innovation remains necessary. "patients are still declining. So while they may be clearing the amyloid, they are not, you know, it's not curing the disease." — Rachel Lennington: On why amyloid-targeting therapies may be insufficient on their own. "What we're trying to do is help make those neurons healthier. And then they're better able to battle the disease." — Rachel Lennington: On the intended therapeutic effect of HGF/MET positive modulation.

Implications: The interview frames Alzheimer’s and related neurodegenerative diseases as biologically complex and likely to require multi-target approaches. If Athera’s data readouts are positive, HGF/MET modulation could validate a new mechanism beyond amyloid/tau and reshape investor and R&D interest in neurodegeneration.